Scotomas in molecular virology and epidemiology of hepatitis C virus

World Journal of Gastroenterology

Volumn 19, Issue 44, 2013, Pages 7910-7921

  Wang, Yue ^a,b  

^a National Institute for Viral Disease Control and Prevention   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Epidemiology; Hepatitis C virus; Hepatitis C virus lifecycle; Hepatitis C virus models; Molecular virology

Indexed keywords

CASEIN KINASE II; COMPLEMENTARY DNA; LOW DENSITY LIPOPROTEIN; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; MITOCHONDRIAL PROTEIN; NONSTRUCTURAL PROTEIN 3; POLYPROTEIN; RNA; STRUCTURAL PROTEIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CELL CULTURE; CLINICAL ASSESSMENT; GENOME ANALYSIS; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MEDICAL TECHNOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PATHOGENESIS; RNA REPLICATION; SCOTOMA; SEQUENCE ANALYSIS; TRANSLATION REGULATION; VIROLOGY;

EPIDEMIOLOGY; HEPATITIS C VIRUS; HEPATITIS C VIRUS LIFECYCLE; HEPATITIS C VIRUS MODELS; MOLECULAR VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; PHENOTYPE; TREATMENT OUTCOME; VIRAL PROTEINS;

EID: 84888599064     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i44.7910     Document Type: Article

References (123)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562 DOI:10.1126/science.2523562]
2. Alter MJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Moyer LA, Fields HA, Bradley DW. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264: 2231-2235 [PMID: 2170702 DOI:10.1001/jama.1990.034 50170079026]
3. Weiner AJ, Kuo G, Bradley DW, Bonino F, Saracco G, Lee C, Rosenblatt J, Choo QL, Houghton M. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990; 335: 1-3 [PMID: 1967327 DOI:10.1016/0140-6736(90)90134Q]
4. Miller RH, Purcell RH. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci USA 1990; 87: 2057-2061 [PMID: 2156259]
5. Purcell R. The hepatitis C virus: overview. Hepatology 1997; 26: 11S-14S [PMID: 9305657 DOI:10.1002/hep.510260702]
6. Pawlotsky JM. Genetic heterogeneity and properties of hepatitis C virus. Acta Gastroenterol Belg 1998; 61: 189-191 [PMID: 9658605]
7. Niepmann M. Hepatitis C virus RNA translation. Curr Top Microbiol Immunol 2013; 369: 143-166 [PMID: 23463200 DOI:10.1007/978-3-642-27340-7_6]
8. Hellen CU, Pestova TV. Translation of hepatitis C virus RNA. J Viral Hepat 1999; 6: 79-87 [PMID: 10607219 DOI:10.1046/j.1365-2893.1999.00150.x]
9. Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol 2013; 369: 167-198 [PMID: 23463201 DOI:10.1007/978-3-642-27340-7_7]
10. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026]
11. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46 [PMID: 14768714]
12. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol 1994; 19: 222-226 [PMID: 7528758]
13. Purcell RH. Does non-A, non-B hepatitis cause hepatocellular carcinoma? Cancer Detect Prev 1989; 14: 203-207 [PMID: 2559795]
14. Takikawa S, Matsuura Y, Miyamura T. [The present studies of the development of HCV vaccine]. Nihon Rinsho 2001; 59: 1379-1383 [PMID: 11494555]
15. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113 [PMID: 10390360 DOI:10.1126/science.285.5424.110]
16. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974 [PMID: 11110665 DOI:10.1126/science.290.5498.1972]
17. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642 [PMID: 12615904 DOI:10.1084/jem.20021756]
18. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796 [PMID: 15951748 DOI:10.1038/nm1268]
19. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626 [PMID: 15947137 DOI:10.1126/science.1114016]
20. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-12771 [PMID: 10535997 DOI:10.1073/ pnas.96.22.12766]
21. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025 [PMID: 12356718 DOI:10.1093/emboj/cdf529]
22. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805 [PMID: 17325668 DOI:10.1038/nature05654]
23. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941 [PMID: 9794763 DOI:10.1126/science.282.5390.938]
24. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886 [PMID: 19182773 DOI:10.1038/nature07684]
25. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-938 [PMID: 16107832 DOI:10.1038/nature04077]
26. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147]
27. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11: 482-496 [PMID: 23748342 DOI:10.1038/nrmicro3046]
28. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19 Suppl 2: 1-26 [PMID: 22404758 DOI:10.1111/j.1365-2893.2012.01590.x]
29. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI:10.1002/hep.24641]
30. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI:10.1002/ hep.22759]
31. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716 [PMID: 20692693 DOI:10.1016/ S0140-6736(10)60934-8]
32. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI:10.1056/NEJMoa1010494]
33. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI:10.1056/NEJMoa1009482]
34. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 [PMID: 19403902 DOI:10.1056/NEJMoa0806104]
35. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850 [PMID: 19403903 DOI:10.1056/NEJMoa0807650]
36. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI:10.1056/ NEJMoa1012912]
37. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI:10.1056/NEJMoa1013086]
38. Cartwright EJ, Miller L. Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Hepatic Medicine: Evidence and Research 2013; 5: 53-61 [DOI:10.2147/HMER. S48545]
39. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI:10.1038/nature08463]
40. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI:10.1038/nature08309]
41. Krauss S, Walker D, Webster RG. Influenza virus isolation. Methods Mol Biol 2012; 865: 11-24 [PMID: 22528151 DOI:10.1007/978-1-61779-621-0_2]
42. Diane S, Leland, Christine C. Ginocchio. Role of Cell Culture for Virus Detection in the Age of Technology. Clin Microbiol Rev 2007; 20: 49-78 [DOI:10.1128/CMR.00002-06]
43. Thomas HC, Lemon SM, Zuckerman AJ. Viral Hepatitis. 3rd ed. Hoboken: Blackwell Publishing, 2005: 824-840
44. Ito T, Mukaigawa J, Zuo J, Hirabayashi Y, Mitamura K, Yasui K. Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus. J Gen Virol 1996; 77 (Pt 5): 1043-1054 [PMID: 8609470 DOI:10.1099/0022-1317-77-5-1043]
45. Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 1992; 89: 5477-5481 [PMID: 1319062 DOI:10.1073/pnas.89.12.5477]
46. Kato N, Nakazawa T, Mizutani T, Shimotohno K. Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. Biochem Biophys Res Commun 1995; 206: 863-869 [PMID: 7832798]
47. Lanford RE, Sureau C, Jacob JR, White R, Fuerst TR. Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. Virology 1994; 202: 606-614 [PMID: 8030225]
48. Iacovacci S, Manzin A, Barca S, Sargiacomo M, Serafino A, Valli MB, Macioce G, Hassan HJ, Ponzetto A, Clementi M, Peschle C, Carloni G. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. Hepatology 1997; 26: 1328-1337 [PMID: 9362380]
49. Fournier C, Sureau C, Coste J, Ducos J, Pageaux G, Larrey D, Domergue J, Maurel P. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J Gen Virol 1998; 79 (Pt 10): 2367-2374 [PMID: 9780041]
50. Duverlie G, Wychowski C. Cell culture systems for the hepatitis C virus. World J Gastroenterol 2007; 13: 2442-2445 [PMID: 17552027]
51. Carcamo WC, Nguyen CQ. Advancement in the development of models for hepatitis C research. J Biomed Biotechnol 2012; 2012: 346761 [PMID: 22701302 DOI:10.1155/2012/346761]
52. Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, Greenberg HB, Ito S, Liang TJ. Hepatitis C viruslike particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 1999; 117: 1397-1407 [PMID: 10579981 DOI:10.1016/S0016-5085(99)70290-8]
53. Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. PLoS Pathog 2012; 8: e1002696 [PMID: 22654662 DOI:10.1371/journal.ppat.1002696]
54. Wu J, Zhang F, Wang M, Xu C, Song J, Zhou J, Lin X, Zhang Y, Wu X, Tan W, Lu J, Zhao H, Gao J, Zhao P, Lu J, Wang Y. Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses. PLoS One 2010; 5: e15825 [PMID: 21209916 DOI:10.1371/journal.pone.0015825]
55. Liu Y, Liu X, Fang J, Shen X, Chen W, Lin X, Li H, Tan W, Wang Y, Zhao P, Qi Z. Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses. Vaccine 2010; 29: 183-190 [PMID: 21055499 DOI:10.1016/j.vaccine.2010.10.059]
56. Du N, Zhou J, Lin X, Zhang Y, Yang X, Wang Y, Shu Y. Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. J Virol 2010; 84: 7822-7831 [PMID: 20484512 DOI:10.1128/ JVI.00069-10]
57. Zhang Y, Lin X, Wang G, Zhou J, Lu J, Zhao H, Zhang F, Wu J, Xu C, Du N, Li Z, Zhang Y, Wang X, Bi S, Shu Y, Zhou H, Tan W, Wu X, Chen Z, Wang Y. Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLoS One 2010; 5: e9167 [PMID: 20161801 DOI:10.1371/journal. pone.0009167]
58. Zhang Y, Lin X, Zhang F, Wu J, Tan W, Bi S, Zhou J, Shu Y, Wang Y. Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochem Biophys Res Commun 2009; 387: 405-408 [PMID: 19615337 DOI:10.1016/ j.bbrc.2009.07.040]
59. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 2003; 100: 14199-14204 [PMID: 14617769 DOI:10.1073/pnas.2335981100]
60. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100: 7271-7276 [PMID: 12761383 DOI:10.1073/pnas.0832180100]
61. Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol 2006; 87: 1075-1084 [PMID: 16603507 DOI:10.1099/ vir.0.81646-0]
62. Bian T, Zhou Y, Bi S, Tan W, Wang Y. HCV envelope protein function is dependent on the peptides preceding the glycoproteins. Biochem Biophys Res Commun 2009; 378: 118-122 [PMID: 19013428 DOI:10.1016/j.bbrc.2008.11.024]
63. Lin X, Zhang Y, Bi S, Lu J, Zhao H, Tan W, Li D, Wang Y. Hepatitis C virus envelope glycoproteins complementation patterns and the role of the ectoand transmembrane domains. Biochem Biophys Res Commun 2009; 385: 257-262 [PMID: 19464265 DOI:10.1016/j.bbrc.2009.05.068]
64. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, Leroux-Roels G, Rice CM. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 3805-3809 [PMID: 16484368 DOI:10.1073/pnas.0511218103]
65. Prince AM. Non-A, non-B hepatitis viruses. Annu Rev Microbiol 1983; 37: 217-232 [PMID: 6314877 DOI:10.1146/annurev.mi.37.100183.001245]
66. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012; 142: 1279-1287 [PMID: 22537434 DOI:10.1053/ j.gastro.2012.02.016]
67. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004; 39: 1469-1475 [PMID: 15185284 DOI:10.1002/hep.20268]
68. Xie ZC, Riezu-Boj JI, Lasarte JJ, Guillen J, Su JH, Civeira MP, Prieto J. Transmission of hepatitis C virus infection to tree shrews. Virology 1998; 244: 513-520 [PMID: 9601519]
69. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933 [PMID: 11479625 DOI:10.1038/90968]
70. MacArthur KL, Wu CH, Wu GY. Animal models for the study of hepatitis C virus infection and replication. World J Gastroenterol 2012; 18: 2909-2913 [PMID: 22736914 DOI:10.3748/wjg.v18.i23.2909]
71. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov 2007; 6: 991-1000 [PMID: 18049473 DOI:10.1038/nrd2411]
72. Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, Chisari FV. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 2010; 84: 10999-11009 [PMID: 20686033 DOI:10.1128/JVI.00526-10]
73. Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, Silvestry M, Kuhn RJ, Rice CM. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci USA 2013; 110: 9505-9510 [PMID: 23690609 DOI:10.1073/ pnas.1307527110]
74. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003; 37: 65-71 [PMID: 12500190]
75. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 2013; 11: 688-700 [PMID: 24018384 DOI:10.1038/nrmicro3098]
76. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-1067 [PMID: 9734402 DOI:10.1038/2053]
77. Wang Y, Kato N, Jazag A, Dharel N, Otsuka M, Taniguchi H, Kawabe T, Omata M. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology 2006; 130: 883-892 [PMID: 16530526 DOI:10.1053/j.gastro.2005.12.028]
78. Nolandt O, Kern V, Müller H, Pfaff E, Theilmann L, Welker R, Kräusslich HG. Analysis of hepatitis C virus core protein interaction domains. J Gen Virol 1997; 78 (Pt 6): 1331-1340 [PMID: 9191926]
79. Boulant S, Vanbelle C, Ebel C, Penin F, Lavergne JP. Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. J Virol 2005; 79: 11353-11365 [PMID: 16103187 DOI:10.1128/JVI.79.17.11353-11365.2005]
80. Lu WX, Cheng T, Li SW, Pan HR, Shen WT, Chen YX, Zhang T, Zheng Z, Zhang J, Xia NS. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay]. Sheng Wu Gong Cheng Xue Bao 2006; 22: 990-995 [PMID: 17168325]
81. Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q. Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 2012; 8: 823-827 [PMID: 22699438 DOI:10.4161/ hv.20042]
82. Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 2004; 78: 2994-3002 [PMID: 14990718]
83. Voisset C, Dubuisson J. Functional hepatitis C virus envelope glycoproteins. Biol Cell 2004; 96: 413-420 [PMID: 15325070]
84. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003; 100: 6986-6991 [PMID: 12759475 DOI:10.1073/pnas.0832193100]
85. Li Y, Wang J, Kanai R, Modis Y. Crystal structure of glycoprotein E2 from bovine viral diarrhea virus. Proc Natl Acad Sci USA 2013; 110: 6805-6810 [PMID: 23569276 DOI:10.1073/pnas.1300524110]
86. OuYang B, Xie S, Berardi MJ, Zhao X, Dev J, Yu W, Sun B, Chou JJ. Unusual architecture of the p7 channel from hepatitis C virus. Nature 2013; 498: 521-525 [PMID: 23739335 DOI:10.1038/nature12283]
87. Luik P, Chew C, Aittoniemi J, Chang J, Wentworth P, Dwek RA, Biggin PC, Vénien-Bryan C, Zitzmann N. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci USA 2009; 106: 12712-12716 [PMID: 19590017 DOI:10.1073/ pnas.0905966106]
88. Takikawa S, Engle RE, Emerson SU, Purcell RH, St Claire M, Bukh J. Functional analyses of GB virus B p13 protein: development of a recombinant GB virus B hepatitis virus with a p7 protein. Proc Natl Acad Sci USA 2006; 103: 3345-3350 [PMID: 16492760 DOI:10.1073/pnas.0511297103]
89. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19 [PMID: 14752815]
90. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172 [PMID: 16177806 DOI:10.1038/nature04193]
91. Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 2013; 369: 113-142 [PMID: 23463199 DOI:10.1007/978-3-642-27340-7_5]
92. Einav S, Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, Lowe AW, Glenn JS. The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology 2008; 47: 827-835 [PMID: 18081150 DOI:10.1002/hep.22108]
93. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 2008; 26: 1019-1027 [PMID: 18758449 DOI:10.1038/nbt.1490]
94. Thompson AA, Zou A, Yan J, Duggal R, Hao W, Molina D, Cronin CN, Wells PA. Biochemical characterization of recombinant hepatitis C virus nonstructural protein 4B: evidence for ATP/GTP hydrolysis and adenylate kinase activity. Biochemistry 2009; 48: 906-916 [PMID: 19146391 DOI:10.1021/bi801747p]
95. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 1995; 69: 3980-3986 [PMID: 7769656]
96. Hirota M, Satoh S, Asabe S, Kohara M, Tsukiyama-Kohara K, Kato N, Hijikata M, Shimotohno K. Phosphorylation of nonstructural 5A protein of hepatitis C virus: HCV groupspecific hyperphosphorylation. Virology 1999; 257: 130-137 [PMID: 10208927]
97. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S, Engel U, Bartenschlager R. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008; 4: e1000035 [PMID: 18369481 DOI:10.1371/journal. ppat.1000035]
98. Moradpour D, Evans MJ, Gosert R, Yuan Z, Blum HE, Goff SP, Lindenbach BD, Rice CM. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 2004; 78: 7400-7409 [PMID: 15220413 DOI:10.1128/ JVI.78.14.7400-7409.2004]
99. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4: e1000032 [PMID: 18369478 DOI:10.1371/journal.ppat.1000032]
100. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-1097 [PMID: 17721513 DOI:10.1038/ncb1631]
101. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 2008; 82: 7964-7976 [PMID: 18524832 DOI:10.1128/JVI.00826-08]
102. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937-943 [PMID: 10504728 DOI:10.1038/13305]
103. Deore RR, Chern JW. NS5B RNA dependent RNA polymerase inhibitors: the promising approach to treat hepatitis C virus infections. Curr Med Chem 2010; 17: 3806-3826 [PMID: 20858218 DOI:10.2174/092986710793205471]
104. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996; 15: 12-22 [PMID: 8598194]
105. Lohmann V, Körner F, Herian U, Bartenschlager R. Bio-chemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997; 71: 8416-8428 [PMID: 9343198]
106. Knipe DM, Howley PM. Field Virology. 5th ed. Philadelphia: Lippincott Williams and Wilkins Immunology, 2007
107. Fraser CS, Doudna JA. Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol 2007; 5: 29-38 [PMID: 17128284 DOI:10.1038/nrmicro1558]
108. Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol 1992; 66: 1476-1483 [PMID: 1310759]
109. Wang C, Sarnow P, Siddiqui A. A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA. J Virol 1994; 68: 7301-7307 [PMID: 7933114]
110. Kato J, Kato N, Moriyama M, Goto T, Taniguchi H, Shiratori Y, Omata M. Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNA-activated protein kinase-independent pathway. J Infect Dis 2002; 186: 155-163 [PMID: 12134250]
111. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581 [PMID: 16141076 DOI:10.1126/science.1113329]
112. Song Y, Friebe P, Tzima E, Jünemann C, Bartenschlager R, Niepmann M. The hepatitis C virus RNA 3'-untranslated region strongly enhances translation directed by the internal ribosome entry site. J Virol 2006; 80: 11579-11588 [PMID: 16971433 DOI:10.1128/JVI.00675-06]
113. Sainz B, Chisari FV. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 2006; 80: 10253-10257 [PMID: 17005703 DOI:10.1128/JVI.01059-06]
114. Cai Z, Zhang C, Chang KS, Jiang J, Ahn BC, Wakita T, Liang TJ, Luo G. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 2005; 79: 13963-13973 [PMID: 16254332 DOI:10.1128/JVI.79.22.13963-13973.2005]
115. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76: 13001-13014 [PMID: 12438626 DOI:10.1128/JVI.76.24.13001-13014.2002]
116. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009; 4: e8467 [PMID: 20041146 DOI:10.1371/journal.pone.0008467]
117. Tao YL, Tang YF, Qiu JP, Cai XF, Shen XT, Wang YX, Zhao XT. Prevalence of hepatitis C infection among intravenous drug users in Shanghai. World J Gastroenterol 2013; 19: 5320-5325 [PMID: 23983436 DOI:10.3748/wjg.v19.i32.5320]
118. Cohen DE, Russell CJ, Golub SA, Mayer KH. Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior. AIDS Patient Care STDS 2006; 20: 557-564 [PMID: 16893325 DOI:10.1089/ apc.2006.20.557]
119. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562 [PMID: 23817321 DOI:10.1038/nrgastro.2013.107]
120. Imamura M, Chayama K. HCV-HBV infection. Nihon Rinsho 2006; 64: 1310-1313 [PMID: 16838649]
121. Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 2005; 51: 31-46 [PMID: 15756144]
122. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337 [PMID: 23460056 DOI:10.7326/0003-4819-158-5-20130305000005]
123. El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012; 19: 153-160 [PMID: 22329369 DOI:10.1111/j.1365-2893.2011.01563.x]